Insider: BELVIN MARCIA SVP, Chief Scientific Officer - CytomX Therapeutics, Inc.
| Company Holdings |
| Direct | Indirect Ownership | Total | |
| Shares | 272,252 | 0 | 272,252 |
| Value | $789,530.80 | $0.00 | $789,530.80 |
Trans. Date |
Trans. Type |
Shares |
Ownership Type |
Issue Type |
Price |
Trans. Value |
Total Shares Owned |
|---|---|---|---|---|---|---|---|
| 06/16/2025 | DDS | 13,884 | Direct | COM | $2.69 | $37,334.08 | 272,252 |
| 03/18/2025 | DDS | 19,512 | Direct | COM | $0.60 | $11,687.69 | 248,636 |
| 08/20/2024 | DDS | 4,181 | Direct | COM | $1.23 | $5,138.87 | 175,648 |
| 03/19/2024 | DDS | 12,795 | Direct | COM | $2.09 | $26,683.97 | 168,579 |
| 12/20/2023 | DDS | 4,077 | Direct | COM | $1.38 | $5,628.30 | 155,124 |
| 09/22/2023 | DDS | 4,119 | Direct | COM | $1.30 | $5,355.94 | 147,951 |
| 1 You are at page 1 of 1 pages |
|
Transaction Type Key First letter: A = Acquired, D = Disposed Second letter: A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security | D = Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | E = Expiration of short derivative position | F = Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. | G = Gift | H = Expiration (or cancellation) of long derivative position with value received | I = Discretionary transaction in accordance with Rule 16b-3(f) | J = Other | L = Small acquisition under Rule 16a-6 | M = Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | O = Exercise of out-of-the-money derivative security | P = Open market or private purchase | S = Open market or private sale | U = Disposition pursuant to a tender of shares in a change of control transaction | W = Acquisition or disposition by will or the laws of descent and distribution | X = Exercise of in-the-money or at-the-money derivative security | Z = Deposit into or withdrawal from voting trust |
 |
Send to Excel |
© 2000 - 2025 Zacks Investment Research